Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway

Cancer Research

Volumn 71, Issue 20, 2011, Pages 6400-6409

  Daurkin, Irina ^a   Eruslanov, Evgeniy ^a   Stoffs, Taryn ^a   Perrin, George Q ^a   Algood, Chester ^a   Gilbert, Scott M ^a   Rosser, Charles J ^b   Su, Li Ming ^a   Vieweg, Johannes ^a   Kusmartsev, Sergei ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYICOSATETRAENOIC ACID; 15 LIPOXYGENASE 1; 15 LIPOXYGENASE 2; ARACHIDONATE 15 LIPOXYGENASE; CD11B ANTIGEN; CD15 ANTIGEN; CD163 ANTIGEN; CD206 ANTIGEN; CD33 ANTIGEN; CD36 ANTIGEN; CD40 ANTIGEN; CD45 ANTIGEN; CD68 ANTIGEN; CD83 ANTIGEN; CYCLOOXYGENASE 2; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ESTERASE; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; MANNOSE RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E2; T6 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

15 LIPOXYGENASE 1 GENE; 15 LIPOXYGENASE 2 GENE; 15 LOX1 GENE; 15 LOX2 GENE; ANTIGEN EXPRESSION; ARACHIDONIC ACID METABOLISM; ARTICLE; BONE MARROW CELL; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; COX2 GENE; CTLA 4 GENE; CYTOKINE PRODUCTION; EICOSANOID PRODUCTION; ENZYME INHIBITION; FOXP3 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; ICOSANOID METABOLISM; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY INFILTRATE; KIDNEY CARCINOMA; LYMPHOCYTIC INFILTRATION; MACROPHAGE FUNCTION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TGF BETA1 GENE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

AGED; ARACHIDONATE 15-LIPOXYGENASE; CARCINOMA, RENAL CELL; CELLS, CULTURED; CHEMOKINE CCL2; CTLA-4 ANTIGEN; CYCLOOXYGENASE INHIBITORS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-10; KIDNEY NEOPLASMS; LIPOXYGENASE INHIBITORS; MACROPHAGES; MALE; MIDDLE AGED; NITROBENZENES; NORDIHYDROGUAIARETIC ACID; SULFONAMIDES;

EID: 80054017653     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1261     Document Type: Article

References (41)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics. CA Cancer J Clin 2010;60:277-300.
2. Rini B, Campbell S, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119-32.
3. Yang JC, Childs R. Immunotherapy for renal cell cancer. J Clin Oncol 2006;24:5576-83. (Pubitemid 46631338)
4. Kusmartsev S, Vieweg J. Enhancing efficacy of cancer vaccines in urologic oncology: new directions. Nat Rev Urol 2009;6:540-9.
5. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007;117:1155-66. (Pubitemid 46718400)
6. Qian B, Pollard J. Macrophage diversity enhances tumor progression and metastasis. Cell 2010;141:39-51.
7. Biswas S, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010;11:889-96.
8. Kusmartsev S, Gabrilovich D. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 2005;174:4880-91.
9. Movahedi K, Laoui D, Gysemans C, Baeten M, Van den Bossche J, Mack M, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C (high) monocytes. Cancer Res 2010;70:5728-39.
10. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
11. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182:4499-506.
12. Wang D, Dubois R. Eicosanoids and cancer. Nat Rev Cancer 2010;10:181-93.
13. Eruslanov E, Kaliberov S, Daurkin I, Kaliberova L, Buchsbaum D, Vieweg J, et al. Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J Immunol 2009;182:7548-57.
14. Van den Hove L, Van Gool S, Van Poppel H, Baert L, Coorevits L, Van Damme B, et al. Phenotype, cytokine production and cytolytic capacity of fresh (un-cultured) tumor-infiltrating T lymphocytes in human renal cell carcinoma. Clin Exp Immunol 1997;109:501-9. (Pubitemid 27402320)
15. Deerwish IH, Tannebaum CS, Rayman PA, Finke JH. Mechanisms of immune dysfunction in renal cell carcinoma. Cancer Treat Res 2003;116:29-51.
16. Corzo C, Condamine T, Lu L, Cotter M, Youn J, Cheng P, et al. HIF-1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010;207:2439-53.
17. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006;25:315-22. (Pubitemid 44922352)
18. Mosser D, Edwards J. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008;8:958-69.
19. Whiteside T. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27:5904-12.
20. Attig S, Hennenlotter J, Pawelec G, Klein G, Koch S, Pircher H, et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinoma. Cancer Res 2009;69:8412-9.
21. Cheon E, Khazaie K, Khan M, Strouch M, Krantz S, Phillips J, et al. Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta 468 mice. Cancer Res 2011;71:1627-36.
22. Kuhn H, O'Donnel V. Inflammation and immune regulation by 12/15-lipoxygenases. Prog Lipid Res 2006;45:334-56. (Pubitemid 43818131)
23. Potula H, Wang D, Quyen D, Singh N, Kundumani-Sridharan V, Karpurapu M, et al. Src-dependent STAT-3-mediated expression of monocyte chemoattractant protein-1 is required for 15(S)-hydroxyeicosatetraenoic acid-induced vascular smooth muscle cell migration. J Biol Chem 2009;284:31142-55.
24. Kayama Y, Minamino T, Toko H, Sakamoto M, Shimizu I, Takahashi H, et al. Cardiac 12/15 lipoxygenase-induced inflammation is involved in heart failure. J Exp Med 2009;206:1565-74.
25. Ruhrberg C, De Palma M. A double agent in cancer: deciphering macrophage roles in human tumors. Nat Med 2010;16:861-2.
26. Steidl C, Lee T, Shah S, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875-85.
27. Schwandt A GJ, Elson P, Wyckhouse J, Finke JH, Ireland J, Triozzi P, et al. Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining. J Clin Immunol 2011;31:690-8.
28. Brash A. Lipoxygenases: occurrence, functions, catyalysis and acquisition of substrate. J Biol Chem 1999;274:23679-82.
29. Serhan C, Chiang N, Van Dyke T. Resolving inflammation: dual antiinflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-61. (Pubitemid 351595216)
30. Middleton M, Zukas A, Rubinstein T, Kinder M, Wilson E, Zhu P, et al. 12/15-lipoxygenase-dependent myeloid production of interleukin-12 is essential for resistance to chronic toxoplasmosis. Infect Immun 2009;77:5690-700.
31. Middleton M, Zukas A, Rubinstein T, Jacob M, Zhu P, Zhao L, et al. Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease. J Exp Med 2006;203:2529-40. (Pubitemid 44664622)
32. Wei C, Zhu P, Shah S, Blair I. 15-oxo-Eicosatetraenoic acid, a metabolite of macrophage 15-hydroxyprostaglandin dehydrogenase that inhibits endothelial cell proliferation. Mol Pharmacol 2009;76:516-25.
33. Shureiqi I, Wu Y, Chen D, Yang X, Guan B, Morris J, et al. Determination of endogenous tissue inflammation profiles by LC/MS/MS: COX- and LOX-derived bioactive lipids. Cancer Res 2005;65:11486-92.
34. Rydberg E, Krettek A, Ullstrom C, Ekstrom K, Svensson P, Carlsson L, et al. Hypoxia increases LDL oxidation and expression of 15-lipoxygenase-2 in human macrophages. Arterioscler Thromb Vasc Biol 2004;24:2040-5. (Pubitemid 39482427)
35. Suraneni M, Schneider-Broussard R, Moore J, Davis T, Maldonado C, Li H, et al. Transgenic expression of 15-lipoxygenase 2 (15-LOX2) in mouse prostate leads to hyperplasia and cell senescence. Oncogene 2010;29:4261-75.
36. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L, et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998;28:359-69. (Pubitemid 28048306)
37. Melief C. Cancer immunotherapy by dendritic cells. Immunity 2008;29:372-83.
38. Lu L, Rudensky A. Molecular orchestration of differentiation and function of regulatory T cells. Genes Dev 2009;23:1270-82.
39. Krummel M, Allison J. CD28 and CTLA-4 have opposing effect on response of T cells to stimulation. J Exp Med 1995;182:459-65.
40. Peggs K, Quezada S, Allison J. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008;224:141-65.
41. Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med 2007;204:239-43. (Pubitemid 46294539)